{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:56:34Z","timestamp":1790207794219,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Otsuka Pharmaceutical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Acute myeloid leukemia (AML) is primarily a disease of the elderly, with increasing age associated with worse outcomes. Treatment options include intensive chemotherapy, hypomethylating agents with\/without venetoclax, and best supportive care. Although the treatment landscape for AML has progressed in recent years, survival in older, frail patients ineligible for intensive chemotherapy remains poor. To address this, a panel of European experts convened to discuss the key factors influencing AML prognosis in older patients and\/or those deemed unfit for intensive therapy. The panel shared perspectives on AML outcomes, patient fitness, treatment choices, and unmet needs. Experts agreed that although age is an important factor in guiding therapeutic decision making, other factors should also be considered such as comorbidities and the impact of disease biology (e.g., cytogenetic\/molecular aberrations). Experts also agreed that more robust assessments of patient fitness are required, such as the utilization of geriatric assessment tools. As choice of therapy and its associated toxicities can impact patient\u2019s quality of life (QoL), the logistical, psychosocial, and financial challenges experienced by the patient and their support network needs to be considered when determining treatment. Finally, experts agreed that outcomes in older, unfit patients with AML remain suboptimal in part due to the impact of treatment-related toxicities and QoL burden. There is therefore an urgent need for alternative treatments which minimize toxicity and reduce QoL burden.<\/jats:p>","DOI":"10.3389\/fonc.2025.1642472","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:48:27Z","timestamp":1761907707000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel"],"prefix":"10.3389","volume":"15","author":[{"given":"Felicetto","family":"Ferrara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Geissler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pau","family":"Montesinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Venditti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"B1","unstructured":"Key statistics for acute myeloid leukemia (AML)\n          \n          \n          \n          2024"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","unstructured":"Acute myeloblastic leukemia: A guide for patients\n          \n          \n          \n          2011"},{"key":"B4","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"B5","unstructured":"Acute myeloid leukemia (AML) recent trends in SEER age-adjusted incidence rates"},{"key":"B6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/1947601911408076","article-title":"Genetic abnormalities and challenges in the treatment of acute myeloid leukemia","volume":"2","author":"Kumar","year":"2011","journal-title":"Genes Cancer"},{"key":"B7","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2217\/fon-2022-1286","article-title":"Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review","volume":"19","author":"Heuser","year":"2023","journal-title":"Future Oncol"},{"key":"B8","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","article-title":"Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges","volume":"36","author":"Shallis","year":"2019","journal-title":"Blood Rev"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2009.04.002","article-title":"Acute myelogenous leukemia","volume":"37","author":"Shipley","year":"2009","journal-title":"Exp Hematol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.annonc.2020.02.018","article-title":"Acute myeloid leukemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Heuser","year":"2020","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-022-01299-9","article-title":"Older patients with acute myeloid leukemia deserve individualized treatment","volume":"24","author":"de Leeuw","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B13","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41408-021-00425-3","article-title":"Acute myeloid leukemia: current progress and future directions","volume":"11","author":"Kantarjian","year":"2021","journal-title":"Blood Cancer J"},{"key":"B14","article-title":"Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance","volume":"110","author":"Sobas","year":"2024","journal-title":"Hematologica"},{"key":"B15","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023020630","article-title":"Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial","volume":"142","author":"Freeman","year":"2023","journal-title":"Blood"},{"key":"B16","unstructured":"Venclyxto (venetoclax)"},{"key":"B17","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B19","article-title":"A systematic review of venetoclax for the treatment of unfit AML patients in real-world: is all that glitters gold","volume":"104","author":"Solana-Altabella","year":"2024","journal-title":"Ann Hematol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.3390\/cancers15184618","article-title":"Venetoclax with hypomethylating agents in newly diagnosed acute myeloid leukemia: A systematic review and meta-analysis of survival data from real-world studies","volume":"15","author":"Ucciero","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3389\/fonc.2015.00280","article-title":"Defining and treating older adults with acute myeloid leukemia who are ineligible for intensive therapies","volume":"5","author":"Pettit","year":"2015","journal-title":"Front Oncol"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023022611","article-title":"Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action","volume":"143","author":"Bhatt","year":"2024","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024013744","article-title":"Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of european leukemia net","volume":"9","author":"Venditti","year":"2025","journal-title":"Blood Adv"},{"key":"B24","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2012.303","article-title":"Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making","volume":"27","author":"Ferrara","year":"2013","journal-title":"Leukemia"},{"key":"B25","doi-asserted-by":"crossref","first-page":"386","DOI":"10.3390\/cancers16020386","article-title":"Adapting the fitness criteria for non-intensive treatments in older patients with acute myeloid leukemia to the use of venetoclax-hypomethylating agents combination-practical considerations from the real-life experience of the hematologists of the rete ematologica lombarda","volume":"16","author":"Rossi","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.clml.2020.07.002","article-title":"Usefulness of charlson comorbidity index to predict early mortality and overall survival in older patients with acute myeloid leukemia","volume":"20","author":"Dhakal","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B27","doi-asserted-by":"crossref","DOI":"10.1111\/j.1365-2141.2006.06476.x","article-title":"The hematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukemia","volume":"136","author":"Giles","year":"2007","journal-title":"Br J Haematol"},{"key":"B28","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2012-12-471680","article-title":"Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia","volume":"121","author":"Klepin","year":"2013","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2024013685","article-title":"Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy","volume":"8","author":"Hoff","year":"2024","journal-title":"Blood Adv"},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024025409","article-title":"Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"Dohner","year":"2024","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"crossref","first-page":"e390018","DOI":"10.1200\/EDBK_390018","article-title":"Older adults with newly diagnosed AML: hot topics for the practicing clinician","volume":"43","author":"Lai","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B34","unstructured":"Global quality of life survey\n          \n          \n          \n          2023"},{"key":"B35","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2022007223","article-title":"Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications","volume":"6","author":"Dohner","year":"2022","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-1183","article-title":"Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine","volume":"28","author":"Pollyea","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B37","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"B38","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","author":"Montesinos","year":"2022","journal-title":"N Engl J Med"},{"key":"B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"crossref","first-page":"1160966","DOI":"10.3389\/fonc.2023.1160966","article-title":"Exploring preferences of different modes of administration of hypomethylating agent treatments among patients with acute myeloid leukemia","volume":"13","author":"Delmas","year":"2023","journal-title":"Front Oncol"},{"key":"B41","doi-asserted-by":"crossref","first-page":"107353","DOI":"10.1016\/j.leukres.2023.107353","article-title":"Economic burden during remission and after relapse among older patients with newly diagnosed acute myeloid leukemia without hematopoietic stem cell transplant: A retrospective study using the SEER-Medicare database","volume":"132","author":"Brunner","year":"2023","journal-title":"Leuk Res"},{"key":"B42","article-title":"Phase I\/II study of decitabine, venetoclax, and quizartinib triplet combination in FLT3-ITD mutated AML. Oral presentation (Abstract S142) at EHA 2025","author":"Yilmaz","year":"2025"},{"key":"B43","volume-title":"All-oral decitabine-cedazuridine (DEC-C) + venetoclax (VEN) in patients with newly diagnosed acute myeloid leukemia (AML) ineligible for induction chemotherapy: Phase 1\/2 clinical trial results. Oral presentation (Abstract S135) at EHA 2025","author":"Roboz","year":"2025"},{"key":"B44","volume-title":"Twice weekly low dose decitabine plus venetoclax versus azacytidine plus venetoclax in the frontline treatment of acute myeloid leukemia, ineligible for intensive chemotherapy. Poster presentation (Abstract PS1526) at EHA 2025","author":"Ciprian","year":"2025"},{"key":"B45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","article-title":"Recent advances in targeted therapies in acute myeloid leukemia","volume":"16","author":"Bhansali","year":"2023","journal-title":"J Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642472\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T10:48:34Z","timestamp":1761907714000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1642472\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,31]]},"references-count":45,"alternative-id":["10.3389\/fonc.2025.1642472"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1642472","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,31]]},"article-number":"1642472"}}